Information about 6 peptides in the US

 

Here’s a concise, safety‑first overview of the six peptides you mentioned. All six are unapproved for any medical use by the U.S. FDA as of October 29, 2026. An FDA advisory panel (PCAC) in July 2026 recommended that compounding pharmacies be allowed to make these six under Section 503A, but that vote is advisory only; FDA must still complete formal rulemaking, so U.S. prescribing/compounding has not broadly changed yet. Athletes: several of these are banned in sport. (fda.gov)

BPC‑157

• What it is: A 15–amino acid synthetic peptide derived from a gastric protein fragment; marketed for “healing” across tissues.
• Evidence: Robust animal data; human evidence remains very limited and low quality; FDA’s briefing flagged insufficient safety/efficacy data. Recent reviews found no completed, peer‑reviewed randomized human trials with published results. (fda.gov)
• U.S. status: Not FDA‑approved; PCAC “yes” vote does not change that until rulemaking finishes. (bipc.com)
• Sport: Prohibited under WADA’s S0 (non‑approved substances). (medsafe.govt.nz)
• Key safety notes: FDA highlighted immunogenicity/impurity concerns and a lack of human safety data for common routes. (fda.gov)

TB‑500 (thymosin‑β4 fragment)

• What it is: A 7–amino acid fragment (Ac‑LKKTETQ) of thymosin‑β4; often promoted for wound/tendon/muscle repair.
• Evidence: Preclinical support; limited human work is topical (thymosin‑β4 eye drops, not “TB‑500” injections) with small studies in corneal disease—exploratory, not general proof of benefit. (pmc.ncbi.nlm.nih.gov)
• U.S. status: Not FDA‑approved; PCAC “yes” vote does not make it compoundable yet. (bipc.com)
• Sport: Explicitly banned—WADA names thymosin‑β4 and derivatives (e.g., TB‑500) under S2. (wada-ama.org)
• Key safety notes: FDA raised aggregation/impurity and immunogenicity risks for compounded products. (fda.gov)

Epitalon (Epithalon)

• What it is: A synthetic tetrapeptide (Ala‑Glu‑Asp‑Gly; “AEDG”), often marketed for “anti‑aging/telomeres.”
• Evidence: In‑vitro telomerase/telomere effects are reported; human clinical evidence is sparse and largely from one research network, with no large, independent RCTs. Telomerase activation carries theoretical cancer risks. (mdpi.com)
• U.S. status: Not FDA‑approved; PCAC “yes” does not equal authorization to compound yet. (bipc.com)

MOTS‑c

• What it is: A mitochondrial‑derived peptide encoded in mtDNA; studied for metabolic effects (e.g., insulin sensitivity) mainly in animals and cells.
• Evidence: Discovery and mechanistic work show metabolic signaling; interventional human data with administered MOTS‑c are minimal to none. (pubmed.ncbi.nlm.nih.gov)
• U.S. status: Not FDA‑approved; PCAC “yes” pending FDA rulemaking. (bipc.com)
• Sport: WADA’s 2025 guidance lists MOTS‑c as an example AMPK activator under the Prohibited List framework. Athletes should confirm with USADA. (wada-ama.org)

KPV

• What it is: A tripeptide (Lys‑Pro‑Val) derived from the C‑terminus of α‑MSH; explored for anti‑inflammatory effects.
• Evidence: Preclinical cell/mouse colitis studies suggest anti‑inflammatory activity via PepT1 transport and NF‑κB/MAPK suppression; modern human trials are lacking. FDA noted limited/no human safety data. (pmc.ncbi.nlm.nih.gov)
• U.S. status: Not FDA‑approved; PCAC “yes” pending rulemaking. (bipc.com)

Semax

• What it is: A heptapeptide ACTH(4‑10) analog (Met‑Glu‑His‑Phe‑Pro‑Gly‑Pro); registered and used intranasally in Russia, but not approved in the U.S. (fda.gov)
• Evidence: Russian clinical literature (e.g., stroke recovery) exists but is small and not up to Western regulatory standards; FDA review judged evidence insufficient for proposed U.S. uses. (alzdiscovery.org)
• U.S. status: Not FDA‑approved; PCAC “yes” pending rulemaking. (bipc.com)
• Sport: Not explicitly named on recent WADA lists; applicability can be ambiguous. Athletes should check with USADA before use. (usada.org)

Practical cautions

• Quality/purity: “Research‑use” vials and many clinic/online products are unapproved drugs; identity, sterility, and dose can be unreliable. FDA has issued multiple warning letters to peptide sellers. (fda.gov)
• Unknown risks: Long‑term safety, drug interactions, pregnancy/lactation risks, and cancer‑promotion potential (especially for angiogenesis‑linked peptides) are not well characterized. FDA’s own summaries for these six highlight major evidence gaps. (fda.gov)
• Sports testing: BPC‑157 is banned (S0) and TB‑500 is banned by name (S2). MOTS‑c is cited as an example under the Prohibited List framework. If you’re subject to testing, confirm current status with USADA. (medsafe.govt.nz)

Bottom line

• As of today, none of these six peptides is FDA‑approved, and despite the July 2026 advisory votes, there’s no final FDA rule allowing routine 503A compounding yet. Human efficacy/safety data are limited for all six. If you’re considering them, discuss with a clinician who can review safer, approved alternatives and your specific risks; athletes should obtain written guidance from their anti‑doping organization first. (fda.gov)